EUVIMEDEUVIMED entdecken
Crossref

Dry Powder Inhalation of Nintedanib in Dibasic Calcium Phosphate for Targeting the Lungs in Pulmonary Fibrosis

Sanjay Singh, Frinto Francis, Mohit Barsain, Naresh Kothuri, Sonia Verma, Himanshu Bansode iD, Chakradhar J V U S, Chunna Yadav, Ashok Kumar Sharma, Baisakhi Moharana, Gautam Panda, Amit Misra iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.4c01190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Sanjay Singh und 11 weiteren Autor:innen. Beteiligte Einrichtung: CSIR-Central Drug Research Institute, Lucknow 226031, India. Hauptthemen laut MEDLINE: Indoles, Pulmonary Fibrosis, Calcium Phosphates, Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, Central Drug Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We prepared three variants of nintedanib dry powder inhalations (DPIs), one with dibasic calcium phosphate dihydrate (CaHPO4·2H2O) and two with lactose monohydrate as the carrier. CaHPO4 is not reported as a DPI excipient. We compared nintedanib pharmacokinetics and efficacy of the CaHPO4 formulation against bleomycin-induced pulmonary fibrosis following oral (3.875 mg/q12h) and DPI (200 μg/12 h) dosing in rats. Blood plasma Cmax, Tmax, and AUC resulting from oral dosing and DPI were 780 versus 147.5 μg/mL, 2.47 versus 2.22 h, and 5562 versus 1094 μg/mL·h, respectively. Drug remaining in the lungs and airways at the end of 12 h of dosing with the DPI (2.41 ± 0.37 μg/g of tissue) was double the amount found after oral dosing (1.25 ± 0.56 μg/g). Lung fibrosis induced in rats using bleomycin was resolved equally well by the two interventions administered q12h for 14 days. We submit that the reduction in systemic exposure to nintedanib and enhanced exposure to target tissue could offer significant therapeutic and safety advantages, and CaHPO4 can be easily developed as an excipient for DPIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesPulmonary FibrosisCalcium PhosphatesLungAnimalsRatsDry Powder InhalersBleomycinMaleAdministration, InhalationPowdersRats, Sprague-DawleyAdministration, Oral

Stichwörter der Autor:innen

aerosoldicalcium phosphatenintedanibpreclinical efficacypreclinical pharmacokineticspulmonary drug delivery

Substanzen

nintedanibIndolesCalcium PhosphatesBleomycinPowderscalcium phosphate, dibasic, anhydrous

Autor:innen und Institutionen

  • CSIR-Central Drug Research Institute, Lucknow 226031, India.
  • Jawaharlal Nehru University (JNU), New Delhi 110067, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.

ORCID-Profile: Himanshu Bansode, Amit Misra

Förderung

  • Council of Scientific and Industrial Research, India
  • Central Drug Research Institute

Zitieren

APA

Singh, S., Francis, F., Barsain, M., Kothuri, N., Verma, S., Bansode, H., J V U S, C., Yadav, C., Sharma, A. K., Moharana, B., Panda, G., & Misra, A. (2025). Dry Powder Inhalation of Nintedanib in Dibasic Calcium Phosphate for Targeting the Lungs in Pulmonary Fibrosis. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01190

Vancouver

Singh S, Francis F, Barsain M, Kothuri N, Verma S, Bansode H, et al. Dry Powder Inhalation of Nintedanib in Dibasic Calcium Phosphate for Targeting the Lungs in Pulmonary Fibrosis. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01190

BibTeX
@article{Singh2025,
  author = {Singh, Sanjay and Francis, Frinto and Barsain, Mohit and Kothuri, Naresh and Verma, Sonia and Bansode, Himanshu and J V U S, Chakradhar and Yadav, Chunna and Sharma, Ashok Kumar and Moharana, Baisakhi and Panda, Gautam and Misra, Amit},
  title = {Dry Powder Inhalation of Nintedanib in Dibasic Calcium Phosphate for Targeting the Lungs in Pulmonary Fibrosis},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.4c01190}
}
Kostenlos starten →